Program
Haemophilus influenzae type b
Also written as “Haemophilus influenzae type b- and meningococcal (vaccine)”, “Haemophilus influenzae type b (Conjugate) (Hib)” and “Haemophilus influenzae type b and meningococcal serogroup C (vaccine)”.
Its studies are mostly in Haemophilus Infections · Diphtheria, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 60 open or running | phase 3since Aug 26, 2005 | Aug 26, 2005 | none ahead |
| CanSino Biologics | 11 open or running | phase 1since Sep 25, 2025 | Sep 25, 2025 | Feb 2029phase 1 · NCT07203755 |
| Novartis | 10 open or running | phase 1since Aug 12, 2008 | Aug 12, 2008 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 26, 2005First study: phase 3 study in Haemophilus InfectionsNew to GlaxoSmithKlineGlaxoSmithKline · NCT00323050 · 468 enrolled · Spain
- Nov 24, 2005Phase 3 study in Haemophilus InfectionsGlaxoSmithKline · NCT00258700 · 478 enrolled · Poland, United Kingdom
- Dec 8, 2005Phase 3 study in Haemophilus InfectionsGlaxoSmithKline · NCT00263653 · 297 enrolled · Spain
- May 4, 20063 phase 3 studies in Haemophilus InfectionsGlaxoSmithKline · NCT00322335, NCT00326118, NCT00327184
- Aug 12, 2008Novartis’s first study: phase 1 study in Haemophilus InfectionsNew to NovartisNovartis · NCT00734565 · 40 enrolled · China
- Sep 25, 2025CanSino Biologics’ first study: phase 1 study in DiphtheriaNew to CanSino BiologicsCanSino Biologics · NCT07203755 · 260 planned · China
Ahead
- Feb 2029Primary completion: phase 1 study in DiphtheriaCanSino Biologics · NCT07203755
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07203755Diphtheria · China | 1 | Recruiting | CanSino Biologics | Feb 2029 | 260 |
| NCT00734565Haemophilus Infections · China | 1 | Completed | Novartis | Oct 2008 | 40 |
| NCT00327184Haemophilus Infections · Finland, Italy | 3 | Completed | GlaxoSmithKline | Nov 2006 | 709 |
| NCT00326118Haemophilus Infections · Australia | 3 | Completed | GlaxoSmithKline | Nov 1, 2007 | 433 |
| NCT00322335Haemophilus Infections · Spain | 3 | Completed | GlaxoSmithKline | Jul 2006 | 230 |
| NCT00263653Haemophilus Infections · Spain | 3 | Completed | GlaxoSmithKline | Mar 2005 | 297 |
| NCT00258700Haemophilus Infections · Poland, United Kingdom | 3 | Completed | GlaxoSmithKline | Jul 2006 | 478 |
| NCT00323050Haemophilus Infections · Spain | 3 | Completed | GlaxoSmithKline | Mar 2005 | 468 |
How it is read
Names in the registry
- “Haemophilus influenzae type b- and meningococcal (vaccine)”, 4 entries
- “Haemophilus influenzae type b (Conjugate) (Hib)”, 1 entry
- “Haemophilus influenzae type b and meningococcal serogroup C (vaccine)”, 1 entry
- “Haemophilus influenzae type b- and meningococcal serogroup C (vaccine)”, 1 entry
- “Haemophilus influenzae type b”, 1 entry
Conditions, from the studies’ own filings
- Haemophilus Infections, 7 studies
- Diphtheria, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.